Tripeptide, α-MSH fragment
KPV
KPV after one dose: 50% at ~2 h, 25% at 4 h, 12.5% at 6 h.
Drawn from the half-life in the app's model, ~2 h. The model's figures
- Compound
- KPV
- Symbol
- KPV
- Family
- Healing peptides
- Parts
- 14
- References
- 12
- Checked
- Last reviewed . Sources are listed below.
How Milligram users log it

3%The joint 22nd most tracked compound in Milligram: of people who track compounds in Milligram logged KPV in the last 90 days.
Schedule
Logged doses
Half of people logged between 250 and 500 mcg per dose; the median was 500 mcg.
Tracked alongside
The share of people logging KPV who also logged each.
From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.
Overview
Sources in this part
KPV is a tripeptide of lysine (K), proline (P) and valine (V), which FDA's briefing describes as naturally produced in the body and as a fragment derived from α-melanocyte-stimulating hormone (α-MSH).1 The free base has the molecular formula C16H30N4O4 and a molecular weight of 342.43 g/mol.1
The app grades the evidence for KPV as emerging. That grade is the app's own: the studies described below were done in cells, human skin samples and animals, and FDA's briefing states that its search "did not identify data, such as clinical studies, on these substances administered in humans".1
A search of ClinicalTrials.gov on 16 November 2026 for KPV returned 0 studies. A Europe PMC search of the same date for KPV, lysine-proline-valine or Lys-Pro-Val in the title, together with patients, clinical trial, volunteers or randomized in the title or summary text or the publication type clinical trial, returned 2 records, a rat study of a KPV hydrogel for oral mucositis (Shao 2021) and the mouse colitis-associated cancer study of Viennois 2016 described below, and neither reports giving KPV to people.
How it works
Signalling in human cells and in mice
Dalmasso and colleagues at Emory University School of Medicine reported in Gastroenterology in 2008 that "Nanomolar concentrations of KPV inhibit the activation of NF-kappaB and MAP kinase inflammatory signaling pathways, and reduce pro-inflammatory cytokine secretion".2 The cells were human intestinal epithelial cells (Caco2-BBE and HT29-Cl.19A) and human T cells (Jurkat) stimulated with pro-inflammatory cytokines.2 The authors write: "We found that KPV acts via PepT1 expressed in immune and intestinal epithelial cells".2
Melanocortin receptors
FDA's briefing states that the biological activities of α-MSH are "mediated primarily by its ability to bind to and activate the melanocortin (MC) receptor subtypes MC1, MC3, MC4, and MC5".1 Several studies tested whether KPV works through them. In mice, Getting, Schiöth and Perretti (William Harvey Research Institute, London, Journal of Pharmacology and Experimental Therapeutics, 2003) report that "The antimigratory effect of KPV was not blocked by the MC3/4-R antagonist" and conclude that "KPV is unlikely to mediate its effects through melanocortin receptors but is more likely to act through inhibition of IL-1beta functions".3 FDA writes that "several lines of evidence suggest that MC receptors are unlikely to be the molecular targets underlying the anti-inflammatory and wound-healing properties of KPV", and that "the molecular targets underlying the pharmacological effects of KPV-related BDSs remain unknown".1
The results are not uniform across studies. Elliott and colleagues (University of Sheffield, Journal of Investigative Dermatology, 2004) report that "No elevation in cyclic AMP was detected in either HaCaT or normal human keratinocytes in response to alpha-MSH, KPV or ACTH peptides", and that in Chinese hamster ovary cells transfected with the MC-1 receptor "alpha-MSH and the KPV peptides elevated intracellular calcium".4
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~2 h
- Bioavailability
- 95%
- Typical dose
- 200–500 mcg/day
- Route
- SubQ, oral
- Time to peak
- ~30 min
Sources in this part
FDA's briefing states that "At the time of this evaluation, the nominator did not submit, and FDA did not identify pharmacokinetic or toxicokinetic studies of KPV (free base) or KPV acetate", and that FDA "did not identify clinical studies in humans assessing pharmacokinetics or pharmacodynamics" of them "via any route of administration".1 The figures in the table below are the app's own and are shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | About 2 hours | No half-life of KPV is reported; FDA identified no pharmacokinetic study of it1 |
| Bioavailability | 95% | No bioavailability figure is reported; in dermatomed human skin, permeation by simple passive diffusion was below the detectable level (limit of detection 0.01 μg/mL)5 |
| Time to peak | About 30 minutes | No time to peak is reported1 |
| Duration of activity | About 6 hours | None of the studies cited here reports a duration of activity |
| Routes | Subcutaneous and oral | No human data by any route; the products proposed in the withdrawn nomination were a topical cream and gel at 0.1%1 |
Human studies
No study in the sources gives KPV to people. FDA states that its "search did not identify data, such as clinical studies, on these substances administered in humans", that the nomination cited nine literature references and "none were studies of KPV administered in humans", and that "No published studies were found in which non-compounded or compounded drug products containing KPV (free base) or KPV acetate were used in humans".1 The table lists the studies in the sources, which used cells, human skin samples or animals. FDA's briefing lists Hiltz and Lipton 1989 among studies of "N-acetylated KPV" and Dalmasso and colleagues 2008 among studies of "KPV dimer" (it also lists that paper among KPV studies), and calls these "out of the scope of this evaluation"; the PubMed summaries of the two papers describe the peptide as alpha-MSH [11-13] (lysine-proline-valine) and as KPV (Lys-Pro-Val).
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Hiltz and Lipton, 19896 | Ear swelling induced by picryl chloride in mice, graded doses of KPV compared with saline and a large dose of corticosteroid | None; mice | Graded doses; amounts and length are not given in the summary text | Alpha-MSH [11-13] "inhibited swelling in a dose-related fashion" |
| Getting and colleagues, 20033 | Crystal-induced peritonitis in mice; also IL-1beta-induced peritonitis, mice with a nonfunctional MC1-R, and macrophages in vitro | None; mice and cultured macrophages | Systemic treatment; amounts and length are not given in the summary text | Fewer polymorphonuclear leukocytes in the peritoneal cavity; in vitro, macrophage release of KC and IL-1beta was inhibited by alpha-MSH and MTII "but not by KPV" |
| Elliott and colleagues, 20044 | Signalling in HaCaT and normal human keratinocytes, and in Chinese hamster ovary cells transfected with the MC-1 receptor | None; human keratinocytes and hamster cells | KPV at 10(-15) to 10(-7) M | No cyclic AMP rise; calcium responses to KPV in HaCaT cells only with PIA, an adenosine agonist; normal keratinocytes responded to KPV, with no PIA condition stated; calcium rose in MC-1 receptor cells |
| Bonfiglio and colleagues, 20067 | Corneal epithelial abrasion in rabbits, phosphate-buffered saline as vehicle control, and cultured rabbit corneal epithelial cells | None; rabbits | KPV 1, 5 or 10 mg/ml (30 μl), two drops four times a day, for 4 days; cells at 0.1, 1 and 10 μM | At 60 hours, "eight out of eight (100%) corneas treated with KPV or SP were completely re-epithelized" (SP is the nitric oxide donor sodium nitroprusside) and none of the placebo corneas were; pre-treatment with L-NAME inhibited the KPV effect; in cultured rabbit corneal cells, viability was stimulated at 1 and 10 µM |
| Dalmasso and colleagues, 20082 | Human cell lines (cytokine-stimulated, NF-kappaB and cytokine read-outs) and DSS- and TNBS-induced colitis in mice | None; human cell lines and mice | Nanomolar KPV in cells; KPV in the mice's drinking water, amount and length not given in the summary text | Oral KPV "reduces the incidence of DSS- and TNBS-induced colitis indicated by a decrease in pro-inflammatory cytokine expression" |
| Kannengiesser and colleagues, 20088 | DSS colitis, CD45RB(hi) transfer colitis, and DSS colitis in mice with a nonfunctional melanocortin-1 receptor (MC1Re/e) | None; mice | Amounts and length are not given in the summary text | In DSS colitis, KPV "led to earlier recovery and significantly stronger regain of body weight"; in MC1Re/e mice it "rescued all animals in the treatment group from death during DSS colitis"; the summary text gives no untreated-group outcome or group sizes |
| Viennois and colleagues, 20169 | Azoxymethane and DSS colitis-associated cancer in wild-type and PepT1-knockout mice, and APC Min/+ mice | None; mice, n = 6 per group (wild-type), 5 per group (PepT1-knockout), 5 to 6 per group (APC Min/+) | KPV 100 μmol/L in drinking water during two DSS cycles; 13 weeks in APC Min/+ mice | Fewer tumours in wild-type mice; not significantly changed in PepT1-knockout mice; "KPV did not decrease the tumor burden" in APC Min/+ mice |
| Pawar and colleagues, 20175 | Delivery across dermatomed human skin with iontophoresis (ITP), microneedles (MN) or both | None; human skin samples | Concentrations and current strengths are not given in the summary text | Passive permeation below detection; "4.4 μg/cm 2 /h" with microneedles; iontophoresis with microneedles raised the rate 35 fold over microneedles alone |
The PubMed records list the research support for Hiltz and Lipton as US Public Health Service (NINDS grant NS-10046), also tagged non-US government, and for Getting and colleagues, Elliott and colleagues and Bonfiglio and colleagues as non-US government; none of the three names a company funder or an author tie to one.6,3,4,7
Deeper analysis: Dalmasso 2008 and Kannengiesser 2008, colitis in mice
Dalmasso and colleagues combined human cell lines with two mouse colitis models. In mice, "KPV was added to drinking water" and inflammation was scored by histology and cytokine mRNA.2 The authors conclude that KPV "might be a new therapeutic agent for IBD".2 The PubMed record lists the work as research supported by the National Institutes of Health (NIDDK grants R01-DK-071594, R01-DK55850, R01-DK-061941 and R24-DK-064399), and lists no commercial funder or author tie.2 The summary text does not state the authors' own limitations, group sizes or doses, and the full text could not be read.
Kannengiesser and colleagues (University of Muenster, Inflammatory Bowel Diseases, 2008) tested KPV in DSS colitis and CD45RB(hi) transfer colitis, and in mice with a nonfunctional melanocortin-1 receptor.8 They report that KPV "showed significant anti-inflammatory effects in 2 murine models of colitis" and that "These effects seem to be at least partially independent of MC1R signaling".8 The record lists the research support as non-US government and names no funder, doses or author tie, and the full text could not be read.8
Deeper analysis: Viennois 2016, tumours in mice
Viennois and colleagues (Georgia State University, Cellular and Molecular Gastroenterology and Hepatology, 2016) gave KPV at 100 μmol/L in drinking water during azoxymethane and DSS cycles, and report that wild-type mice showed "a drastic decrease in colon tumorigenesis" with fewer aberrant crypt foci and less epithelial proliferation, while both groups, which each received DSS, "lost similar amounts of weight during DSS treatment" (n = 6 per group; the paper does not report a safety assessment of KPV).9 In PepT1-knockout mice KPV did not produce the effect, although "a trend for a decreased tumor burden index was seen", and in APC Min/+ mice "KPV did not decrease the tumor burden in the small intestine or in the colon", although inflammation measured by lipocalin-2 "was decreased by KPV treatment".9 Figure legends give n = 6 per group for wild-type mice with and without KPV, n = 5 per group for PepT1-knockout mice and n = 5 to 6 per group for APC Min/+ mice. The authors state that "additional studies are warranted to determine the precise mechanism by which KPV decreases tumorigenesis in this model, and to test whether this tripeptide could be beneficial against human CAC".9 Funding was from the US Department of Veterans Affairs, the National Institute of Diabetes and Digestive and Kidney Diseases and a Crohn's & Colitis Foundation of America fellowship, the authors "disclose no conflicts", and the KPV was supplied by Biopeptide Co, Inc.9
Deeper analysis: Pawar 2017, KPV and human skin
Pawar and colleagues (Auburn University, Journal of Pharmaceutical Sciences, 2017) report that "KPV permeation was less than detectable levels (limit of detection, 0.01 μg/mL) by simple passive diffusion", that microneedle treatment gave a permeation of "4.4 μg/cm 2 /h", and that iontophoresis and iontophoresis with microneedles "increased the permeation rate by 8 and 35 fold, respectively, as compared to MN alone".5 FDA summarises the work as showing that "KPV does not permeate well through skin", and states that "It remains to be determined whether such strategies may also increase the systemic absorption of topically administered KPV (free base) or KPV acetate in vivo".1 The PubMed record lists the research support as US government, non-P.H.S., and names no commercial funder or author tie; the summary text states no limitations of its own.5
Doses reported in studies
No dose of KPV given to people is reported in the sources, because FDA identified no study in humans.1 The app lists a typical dose of 200 to 500 mcg a day, a range that none of the studies in the table below reports using.
| Source | Subject | Route | Amount reported |
|---|---|---|---|
| FDA briefing, withdrawn nomination1 | Proposed compounded product, not a study | Topical | Cream or gel at a strength of 0.1% |
| Bonfiglio and colleagues, 20067 | Rabbits | Topical, eye | 1, 5 or 10 mg/ml, 30 μl, two drops four times a day for 4 days |
| Viennois and colleagues, 20169 | Mice | Drinking water | 100 μmol/L during two DSS cycles; 100 μmol/L for 13 weeks in APC Min/+ mice |
Side effects reported
Sources in this part
No report of a side effect of KPV in people is available in the sources. FDA's Office of Surveillance and Epidemiology searched its FAERS adverse event database and the medical literature through 3 December 2025: "The FAERS search did not retrieve any reports and the literature search did not identify any cases of adverse events".1 A search of FDA's Human Foods Complaint System for 1 January 2004 to 3 December 2025 "did not retrieve cases where KPV was administered".1 FDA adds that FAERS reporting is voluntary and that compounders under section 503A "generally do not report adverse events to FDA".1
FDA states that it did not identify acute toxicity, repeat-dose toxicity, genotoxicity, developmental and reproductive toxicity or carcinogenicity studies of KPV, and concludes that "potential safety risks associated with the use of KPV in humans are unknown".1 On immunogenicity and aggregation, FDA writes that "there is insufficient data to conclude that KPV (free base) or KPV acetate do not present these risks".1
In the AOM/DSS model of colitis-associated cancer, Viennois and colleagues report that KPV-treated and AOM/DSS-only mice, both of which received DSS, "lost similar amounts of weight during DSS treatment" (n = 6 per group), and the paper does not report a safety assessment of KPV.9 None of the other animal studies in the table reports a safety outcome of KPV in its summary text.
Bloodwork and markers
The app lists no markers to monitor for KPV.
Regulatory and anti-doping status
FDA states that there is no applicable United States Pharmacopeia or National Formulary monograph for KPV (free base) or its acetate form, "and neither are a component of an FDA-approved drug".1 A search of the European Pharmacopoeia (11.8 edition, 2025) and the Japanese Pharmacopoeia (18th edition) showed no monograph for either form, and the European Medicines Agency listed no authorised product containing them.1 FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" states that "Bulk drug substances that may present significant safety risks have been placed in category 2 under the interim policies", and lists KPV under "Bulk drug substances nominated but withdrawn", the list of substances previously in category 2 that "were withdrawn by the nominators"; its statement on KPV is "FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration", and the page's content is dated 22 April 2026.10
FDA's briefing, written by FDA staff and dated 12 May 2026, evaluates KPV for the 503A bulk drug substances list. The nomination was withdrawn, and FDA evaluated both forms on its own initiative.1 FDA deems each form "not well-characterized from the physical and chemical characterization perspective" and reports that outsourcing facilities "have not reported compounding drug products containing KPV (free base) or KPV acetate from 2017 to June 2025".1 FDA concludes: "we propose not adding KPV (free base) or KPV acetate to the 503A Bulks List", and adds that it will not issue a final determination "until input from the advisory committee process has been considered and all reviews have been finalized".1
Healio reported that on the Thursday of the 23 and 24 July 2026 meeting of FDA's Pharmacy Compounding Advisory Committee, the committee "voted 8-6-1 twice to place KPV free base and acetate forms on the list" (8 yes, 6 no, 1 abstention, the order Healio uses for its other tallies).11 Healio notes that the committee "has faced scrutiny for having several members with conflicts of interest".11 A committee member who voted no, Maral Kibarian Skelsey, said: "I voted 'no' because the clinical indications and the efficacy are not well defined", that "the formulation and the chemical characterization is again not well defined, and as a topical agent, it's not clear that we have any information about the absorption as well as allergenicity", and that "the potential for immunogenicity needs to be addressed and examined".11 A member who voted yes, Asare B. Christian, said he voted yes "in the context of limited information that we've received" and that "There were no significant risk issues raised with this peptide".11 The emergency physician Owais Durrani told Healio that "FDA staff reviewers went through all seven compounds and recommended against every one of them", and that "The recommendations are nonbinding, the agency still has to act, and formal rulemaking runs into 2027".11
The World Anti-Doping Agency's 2026 Prohibited List does not name KPV: a search of the list's text for "KPV" on 16 November 2026 returned no match. Its class S0 covers "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use", prohibited at all times, so absence from the list text does not settle the question.12
What is not known
The sources do not report a half-life, time to peak, bioavailability, dose, efficacy or side effect of KPV in people. FDA states that it is "particularly concerned about the lack of any human data on drug products containing these substances administered via any route of administration", and researchers cited by FDA "have suggested that investigational clinical studies are needed to determine whether KPV could be used as a therapeutic intervention to promote healing of skin wounds and ulcers".1 For the corneal healing effect in rabbits, Bonfiglio and colleagues write that "it is not known whether this mechanism is likely to depend on a direct stimulating repairing activity shared by the entire molecule of alpha-MSH".7 The molecular targets of KPV remain unknown according to FDA, and the studies above disagree on whether melanocortin receptors are involved.1,3,4
Frequently asked questions
What is KPV?
KPV is a tripeptide of lysine, proline and valine that FDA's briefing describes as a fragment derived from α-melanocyte-stimulating hormone.1 Its studies in the sources used human cells, human skin samples and animals.2,4 FDA's briefing calls the skin in the Pawar study "human cadaver skin", while the PubMed record says "dermatomed human skin".1,5
What is the half-life of KPV?
No measured half-life of KPV is reported in the sources, and the app lists about 2 hours. FDA identified no pharmacokinetic study of KPV in animals or people.1
Is KPV FDA approved?
No: FDA states that KPV (free base) and KPV acetate are not a component of an FDA-approved drug.1 FDA's briefing proposes not adding either to the 503A Bulks List, and an advisory committee voted 8-6-1 twice (8 yes, 6 no, 1 abstention) to place them on the list, according to Healio, whose report quotes Owais Durrani saying "The recommendations are nonbinding".1,11
Is KPV banned by WADA?
Are there human studies of KPV?
None of the sources reports KPV given to people: FDA states that it "did not identify data, such as clinical studies, on these substances administered in humans".1 The studies in the sources used human and animal cells, human skin samples, mice and rabbits.
How does KPV work?
The mechanism of KPV is not established: FDA states that "the molecular targets underlying the pharmacological effects of KPV-related BDSs remain unknown".1 Dalmasso and colleagues report that KPV acts via the PepT1 transporter in human cells, and Getting and colleagues conclude that KPV is unlikely to act through melanocortin receptors in mice.2,3
Is there human evidence on oral KPV?
What are the side effects of KPV?
Did the FDA advisory committee vote for KPV?
Healio reported that at its 23 and 24 July 2026 meeting the Pharmacy Compounding Advisory Committee voted 8-6-1 twice (8 yes, 6 no, 1 abstention) to place KPV free base and acetate forms on the 503A list, and Healio quotes Owais Durrani saying "The recommendations are nonbinding".11 FDA's own reviewers proposed not adding them, and FDA states it will not issue a final determination until the committee's input has been considered.1
Guides, tools and comparisons
References
- US Food and Drug Administration. Evaluation of KPV-related bulk drug substances (KPV (free base) and KPV acetate) for inclusion on the 503A bulk drug substances list. Briefing document, Pharmacy Compounding Advisory Committee, 23 to 24 July 2026 (dated 12 May 2026). FDA briefing document
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008. PMID 18061177
- Getting SJ, Schioth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther 2003. PMID 12750433
- Elliott RJ, Szabo M, Wagner MJ, et al. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol 2004. PMID 15102092
- Pawar K, Kolli CS, Rangari VK, Babu RJ. Transdermal iontophoretic delivery of lysine-proline-valine (KPV) peptide across microporated human skin. J Pharm Sci 2017. PMID 28343991
- Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J 1989. PMID 2550304
- Bonfiglio V, Camillieri G, Avitabile T, et al. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res 2006. PMID 16965771
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008. PMID 18092346
- Viennois E, Ingersoll SA, Ayyadurai S, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol 2016. PMC4957955
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 of the bulk substances nominated under sections 503A or 503B). Content current as of 22 April 2026. FDA safety-risk page
- Healio. FDA committee recommends looser restrictions for several peptides. 24 July 2026. Healio report
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026